Table 1.

Patient characteristics, treatment status, prognostic information, and dasatinib response

Pt. no.SexAgeTherapyRai stageZAP-70IGHVCytogenetic abnormalitiesDasatinib response*
CLL001M47T1+Unmutdel(13q14.3), del(11q)Good
CLL003M76NT1+MutTrisomy 12Good
CLL004F58NT0Mutdel(13q14.3)Poor
CLL005M58NT1N/AMutdel(13q14.3)Poor
CLL006F76NT3N/AN/AN/APoor
CLL007M60NT2+Unmutdel(13q14.3)Good
CLL010N/A62NTN/A+N/AN/AGood
CLL011M42T1+Unmutdel(13q14.3)Good
CLL014F63T1Mutdel(13q14.3), del(11q)Poor
CLL015F56T1+MutTrisomy 12Good
CLL016F57NT0Mutdel(13q14.3)Good
CLL018F71NT1MutTrisomy 12Good
CLL019M72NT1Mutdel(13q14.3)Poor
CLL020M63NT2Unmutdel(6q)Poor
CLL021F55NT2+MutNonePoor
CLL022M81T1MutNoneGood
CLL024M70T1N/AUnmutN/AGood
CLL029F71T3+Unmutdel(13q14.3), del(11q)Good
CLL030M60NT1+UnmutTrisomy 12, del(11q)Good
CLL031M60NT1+Mutdel(13q14.3), del(11q)Good
CLL032M64NT1Mutdel(13q14.3)Poor
CLL035M64NT0MutNonePoor
CLL037F72NT0Mutdel(13q14.3)Poor
CLL038M67T1+Mutdel(11q)Good
CLL039F67T1N/AMutdel(13q14.3)Poor
CLL042F60NT2Mutdel(13q14.3)Poor
CLL044F67NT0+MutNonePoor
CLL050M88T4+Mutdel(13q14.3), trisomy 12Good
CLL051F73NT0N/AN/AN/APoor
CLL055M74T1+Unmutdel(17p)Good
CLL057M63NT3+MutNonePoor
CLL062M74T4+Unmutdel(11q)Good
CLL064M70NT1Mut13q(14.3)Poor
CLL067F59NT1Mut13q(14.3)Poor
CLL078F75NT0MutN/APoor
CLL085M66T4N/AUnmutdel(13q14.3), del(11q)Poor
CLL087M79NT0Mutdel(13q14.3)Poor
CLL091M73NT1N/AN/ANonePoor
CLL092M39NT1+Unmutdel(13q14.3), del(11q)Good
CLL095F78NT1Unmutdel(17p), del(13q14.3)Good
CLL097M65T1+Unmutdel(13q14.3)Good
CLL098M55NT1+Unmutdel(17p)Good
CLL120F49NT1N/AN/ANoneGood
CLL113F63NT2+UnmutNoneGood
CLL117M70T2+UnmutN/AGood
CLL118M82NT2UnmutTrisomy 12Poor
CLL124F60NT0MutN/APoor
CLL126M60NT0Mutdel(13q14.3)Poor
CLL125F57NT4Unmutdel(13q14.3)Good
CLL127F80NT1Mutdel(13q14.3)Poor

Abbreviations: Pt., patient; M, male; F, female; T, treated; NT, not treated; N/A, not available; Unmut, unmutated; Mut, mutated.

  • *Good responders were defined as those that had a >24% difference in viability between treated and untreated cells throughout the entire time course of treatment (n = 25). Poor responders were those that had <24% difference in viability (n = 25).